Published in Healthcare Mergers, Acquisitions and Ventures Week, October 6th, 2007
This trend article is an immediate alert from NewsRx to identify the most recent news developments at Portola Pharmaceuticals, Inc.
Report 1: Portola Pharmaceuticals, Inc. announced that it will present clinical and preclinical data on its oral Factor Xa inhibitor and on its intravenous and oral ADP receptor antagonist at the XXI Congress of the International Society of Thrombosis and Haemostasis (ISTH) in Geneva, Switzerland on July 6 through July 12, 2007.
Report 2: Portola Pharmaceuticals, Inc. presented Phase I data of its ADP receptor...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Healthcare Mergers, Acquisitions and Ventures Week